Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Relapsed/Refractory DLBCL: Unmet Needs

July 17th 2020

BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

July 17th 2020

BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

July 17th 2020

Emerging Treatments for Relapsed/Refractory DLBCL

July 17th 2020

Lenalidomide-Refractory Multiple Myeloma

July 17th 2020

SADAL Trial Regimen FDA Approval

July 17th 2020

SADAL Trial Overview

July 17th 2020

Daratumumab With Carfilzomib in Frontline Multiple Myeloma

July 17th 2020

CAR T-Cell Therapy Clinical Trials

July 17th 2020

Management of Relapsed/Refractory Multiple Myeloma

July 17th 2020

CAR T-Cell Therapy Response Rates

July 17th 2020

Maintenance Therapy Approaches in Multiple Myeloma

July 17th 2020

CAR T Cell Therapy in Relapsed/Refractory DLBCL

July 17th 2020

MRD Monitoring in Multiple Myeloma

July 17th 2020

Relapsed/Refractory DLBCL Treatment Landscape

July 17th 2020

The Role of Transplant in Multiple Myeloma

July 17th 2020

Treating Transplant-Eligible and -Ineligible MM

July 17th 2020

R/R DLBCL: Transplant Eligibility and R-CHOP

July 17th 2020

Transplant-Ineligible Multiple Myeloma

July 17th 2020

Newly Diagnosed DLBCL: Treatment Decision Factors

July 17th 2020